Steven O’Day: I am thrilled to announce the upcoming launch of “The Immuno-Oncology Curve”

Steven O’Day, the Chief Medical Officer of Agenus, shared on LinkedIn:

“I am thrilled to announce the upcoming launch of “The Immuno-Oncology Curve,” a podcast series dedicated to keeping you ahead of the curve on the latest in immunotherapy. I will be sharing the mic with colleagues, patients, advocates and global leaders in oncology who share a common goal – to lengthen the survival curve for patients.

In our inaugural episode, I had an insightful an exciting and thought-provoking conversation with Dr. Alexander (Lex) Eggermont MD, PhD.

I’ll share an update once the episode is available. Stay tuned!”

Source: Steven O’Day / LinkedIn

Steven O’Day serves as Agenus’ Chief Medical Officer. He is responsible for leading the expansion of the company’s presence in the I-O field. A pioneer in CTLA-4 inhibition, Dr. O’Day played key roles in the advancement of cancer therapies Yervoy and Opdivo, and has been the principal investigator in more than 200 clinical trials. Prior to joining Agenus, he was Executive Director of the John Wayne Cancer Institute and Cancer Clinics at Providence St. John’s Health Center, and Director of the Melanoma and Cutaneous Oncology Research Center. Steven was a visiting scholar in philosophy and medical ethics at Oxford, received his MD from Johns Hopkins, and was a Fellow at the Dana Farber/Harvard Cancer Center.